National Drug Dependence Treatment Center (NDDTC), Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Institute of Liver and Biliary Sciences (ILBS), New Delhi.
J Psychoactive Drugs. 2020 Jan-Mar;52(1):93-100. doi: 10.1080/02791072.2019.1709000. Epub 2020 Jan 2.
This article reviews the provisions of Indian national policy on narcotic drugs and psychotropic substances in context of the health sector services for (illicit) psychoactive substances and substance use disorders (SUD). For the the current review, a checklist was developed based on recommendations from various agencies and organizations. The document on Indian national policy on narcotic drugs and psychotropic substances was reviewed based on the checklist. Themes such as identification in the aims/objectives/vision of the policy, including those highlighting treatment-related needs for SUD; establishment of minimum standards of care for treatment; evaluation of treatment programs for SUD; government regulation of public and private drug treatment services; capacity building for treatment services; and harm reduction services to reduce bloodborne infections were documented in the policy. Others such as transparency of the policy making process; situation analysis; implementation of substance abuse prevention and treatment programs that target key populations; impetus on evidence-based programs and practices were inadequately documented. Finally, integration of treatment into existing health care systems; services for co-occurring disorders (medical and psychiatric); monitoring and performance evaluation of prevention programs; harm reduction services to reduce overdose; budget allocations and provisions for implementation were not documented in the current policy.
本文结合卫生部门为(非法)精神活性物质和物质使用障碍(SUD)提供的服务,审查了印度国家麻醉药品和精神药物政策的规定。为了本次审查,根据各机构和组织的建议制定了一份检查表。根据该检查表审查了关于印度国家麻醉药品和精神药物政策的文件。该政策中记录了一些主题,如政策目标/目的/愿景中的识别,包括突出 SUD 治疗相关需求的内容;确立治疗 SUD 的最低标准;评估 SUD 治疗方案;政府对公共和私人药物治疗服务的监管;治疗服务的能力建设;以及减少血源性感染的减少伤害服务。其他方面,如政策制定过程的透明度;情况分析;实施针对重点人群的药物滥用预防和治疗计划;对基于证据的计划和实践的推动,记录不足。最后,在现行政策中没有记录将治疗纳入现有医疗保健系统;针对共病(医学和精神病学)的服务;预防计划的监测和绩效评估;减少过量用药的减少伤害服务;预算分配和实施规定。